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Introduction {#sec1}
============

A novel coronavirus (CoV), designated severe acute respiratory syndrome (SARS)-CoV-2, underlies a pandemic infection, coronavirus disease 2019 (COVID-19), which rapidly spread globally and has been proclaimed a severe public health emergency of international concern (PHEIC) by the World Health Organization (WHO) ([@bib26]). By June 30, 2020, more than 200 countries and territories reported COVID-19 infections, together comprising 10,185,374 confirmed cases and 503,862 deaths (data from WHO, the Centers for Disease Control and Prevention \[CDC\], and the European Centre for Disease Prevention and Control \[ECDC\] are at <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>).

Common respiratory viruses include CoV, influenza A virus (IAV), influenza B virus, respiratory syncytial virus, parainfluenza virus, adenovirus, etc. CoV belongs to the virus family *Coronaviridae*, which is an enveloped, nonsegmented, single-stranded positive-sense RNA virus ([@bib37]). SARS-CoV-2 is a β-coronavirus, like Middle East respiratory syndrome (MERS)-CoV and SARS-CoV, both of which are also suggested to have originated in bats ([@bib39]). Evidence supports that the cellular receptor angiotensin-converting enzyme 2 (ACE2) and the serine protease for SARS-CoV entry, transmembrane serine protease 2 (TMPRSS2) ([@bib12]), are key mediators for SARS-CoV-2 host cell entry ([@bib27]). It has been shown that *ACE2* is expressed not only in the respiratory system but in a range of organs, tissues, and cell types ([@bib32]), indicating that viral infection can rapidly spread throughout the body as disease progresses.

SARS-CoV first emerged in China in 2002--2003, and MERS-CoV was first reported in Saudi Arabia in 2012, with mortality rates around 10% (8,098 cases and 774 deaths; data from WHO) and 34.4% (2,494 cases and 858 deaths; data from WHO) of SARS-CoV and MERS-CoV, respectively ([@bib30]). In particular, based on the data collected from WHO (up to March 24, 2020), 4.9% of SARS-CoV-2 cases are fatal (823,626 cases and 40,598 deaths), lower than that of MERS-CoV and SARS-CoV ([@bib13]). Flu season occurs annually, and influenza symptoms are similar to respiratory diseases caused by CoVs. According to annual estimates of the burden of seasonal influenza in the United States, the influenza viruses have caused an estimated 9,200,000--35,600,000 illnesses, 139,000--708,000 hospitalizations, and 4,000--20,000 deaths from pneumonia and influenza and 12,000--56,000 deaths from respiratory and circulatory symptoms (data from 2010--2011 to 2015--2016 influenza seasons) with a mortality rate of 0.04%--0.83% ([@bib20]).

SARS-CoV-2 infection diagnostics include pneumonia detection using computed tomography (CT) scans and viral RNA detection (extracted and tested by real-time RT-PCR with SARS-CoV-2-specific primers and probes) in throat swab samples, secretions acquired from the lower respiratory tract, peripheral blood, or feces. Patients with mild symptoms present with fever, cough, myalgia or fatigue, and sputum production, though infected individuals are sometimes asymptomatic. Such mild symptoms rarely include intestinal signs and symptoms ([@bib9]).

After COVID-19 diagnosis, other symptoms can be detected by routine blood examination. The neutrophils in 38% of COVID-19 patients were above the normal range, while the hemoglobin in 51% COVID-19 patients lies below the normal range, according to research at the Jinyintan Hospital in Wuhan, China. In addition, lymphocyte levels decreased in 35% of patients ([@bib2]), suggesting possible dysfunctional cell-mediated immunity in COVID-19 patients.

In addition to acute respiratory distress syndrome (ARDS), virally driven hyperinflammation is another major cause of mortality ([@bib8]). Increased proinflammatory cytokine or chemokine responses even initiated viral sepsis and overwhelming systemic inflammation, contributing to cytokine storm syndromes (CSSs) that include acute inflammatory-induced lung injury and development of pneumonitis, ARDS and respiratory failure resulting in shock, hemodynamic instability, multiple organ dysfunction, and even death. It has been reported that interleukin-6 (IL-6) concentrations and ferritin increase with illness deterioration in non-survivors compared with survivors within a subgroup of patients with COVID-19 ([@bib38]). Furthermore, we recently reported that during the acute phase, a group of proinflammatory cytokines was upregulated in lung injury (Murray score) in severe patients. Importantly, these cytokines can be used as biomarkers to predict disease severity after SARS-CoV-2 infection ([@bib42]).

Although there is accumulating clinical data regarding blood cell indices, underlying molecular mechanisms have yet to be clarified. Here, we report the transcriptome dynamics of peripheral blood mononuclear cells (PBMCs) from patients with COVID-19, comparing these to profiles in IAV patients and control, healthy donors. We examined the landscape and features of these infections by integrating single-cell RNA sequencing (scRNA-seq) with clinical symptoms. We observed an increased proportion of plasma cells, as well as a reduction of lymphocytes in the clinic. Further analyses suggest that XAF1-, tumor necrosis factor (TNF)-, and Fas-induced apoptosis may confer this reduction. Furthermore, distinct from that in IAV patients, expression of *IL6R* and *IL6ST* was upregulated in COVID-19 patients, which synergistically promotes increased proinflammatory cytokines during pathogenesis. We also discovered that several interferon (IFN)-stimulated genes (ISGs; including *ISG15*, *IFI44*, *IFI44L*, and *RSAD2*) were specifically upregulated in PBMCs from COVID-19 patients, enhancing antiviral and immune modulatory functions after viral infection.

Results {#sec2}
=======

Single-Cell Transcriptional Landscape of PBMCs from COVID-19 and IAV Patients {#sec2.1}
-----------------------------------------------------------------------------

To investigate the pathogenesis and mechanism of SARS-CoV-2 infections in COVID-19 patients, blood samples were collected from three healthy controls, two IAV-infected patients, and five COVID-19 patients, including four patients (COV-1 to COV-4) with uncomplicated disease courses and one patient (COV-5) that subsequently progressed to severe disease ([Figure 1](#fig1){ref-type="fig"} A; [Table S1](#mmc2){ref-type="supplementary-material"}). Seasonal IAV-infected patients were chosen as controls because both SARS-CoV-2 and IAV are contagious RNA viruses, and both caused respiratory tract infection. However, COVID-19 has distinct clinical signatures compared to IAV infections, including high morbidity and mortality. COVID-19 patients were enrolled within 5--10 days of symptom onset based on positive nucleic acid testing results, and the day when PBMCs were first collected was named day 1. Time points corresponding to disease onset and sample collection are listed in [Table S1](#mmc2){ref-type="supplementary-material"}. PBMCs were also collected at subsequent time points as shown in [Figure 1](#fig1){ref-type="fig"}A. After filtering out cells with low quality, we obtained transcriptome datasets from 46,022 cells with an average of 2,000 cells for each participant at each time point ([Figure 1](#fig1){ref-type="fig"}B). To uncover immune cell populations in COVID-19, we performed unsupervised clustering and obtained 15 cell populations ([Figure 1](#fig1){ref-type="fig"}C). Immunocytes such as T cells, B cells, monocytes, natural killer (NK) cells, DCs, stem cells, and megakaryocytes were identified based on the expression of classic cell-type markers ([Figure 1](#fig1){ref-type="fig"}C). With this approach, five populations were annotated as T cells, including naive T cells (CD3^+^CCR7^+^GZMA^−^), activated CD4^+^ T cells (CD3^+^CD4^+^IL7R^+^), cytotoxic CD8^+^ T cells (CD3^+^CD8^+^GZMA^+^), mucosal associated invariant T cells (MAIT cells; CD3^+^SLC4A10^+^), and cycling T cells (CD3^+^MKI67^+^); four populations were annotated as B cells, including naive B cells (MS4A1^+^IGHG1^−^), plasma cells (MZB1^+^IGHG1^+^), cycling plasma cells (MZB1^+^IGHG1^+^MKI67^+^), and memory B cells (MS4A1^+^IGHG1^+^); two were annotated as NK cells (KLRF1^+^); and one population was labeled DCs (CD1C^+^LYZ^+^) and monocytes (LYZ^+^CD68^+^) ([Figures 1](#fig1){ref-type="fig"}D and [S1](#mmc1){ref-type="supplementary-material"}A). Most of the clusters consisted of cells from multiple patients, indicating common immune traits among patients. In addition, PBMC samples from patients did not express *ACE2* and *TMPRSS2* receptors and did not exhibit viral reads, indicating that SARS-CoV-2 may not infect PBMCs ([Figure S1](#mmc1){ref-type="supplementary-material"}B).Figure 1Single-Cell Gene Expression Profiling of Immune Cells Derived from PBMCs of the Participants(A) Schematic outline of the study design. 10 subjects, including three healthy donors, five COVID-19 patients, and two IAV-infected patients were included in this study.(B) Bar plot shows the log~10~ transformed cell number of each sample for every donor at different time points. Blue represents three healthy donors, orange represents two IAV-infected patients, and five COVID-19 patients are displayed using five different colors.(C) The clustering result of 46,022 cells from ten donors. Each point represents one single cell, colored according to cell type. Mega., Megakaryocytes.(D) Expression levels of cell typing genes in cell type clusters. CD3G indicates T cells, KLRF1 and XCL1 indicate NKs, MS4A1 indicates B cells, IGHG1 and MZB1 indicate plasma cells, CD68 indicates monocytes, LYZ indicates DCs, MKI67 and TOP2A indicate cycling T cells, GZMA indicates cytotoxic CD8^+^ T cells and NKs, and PPBP indicates megakaryocytes.See also [Figure S1](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc2){ref-type="supplementary-material"}.

Increased Plasma Cells in PBMCs from COVID-19 and IAV Patients {#sec2.2}
--------------------------------------------------------------

The general patterns of PBMC populations were comparable across patients ([Figure 2](#fig2){ref-type="fig"} A; [Table S2](#mmc3){ref-type="supplementary-material"}). The proportion of plasma cells and cycling plasma cells were increased significantly in both COVID-19- and IAV-infected patients ([Figures 2](#fig2){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}), and there was no difference between these two types of virus infection. The increased plasma cells may induce protective neutralizing antibodies to prevent viruses infecting cells. As expected, when examining the functions of upregulated genes in B cells of COVID-19 patients compared with healthy donors, protein complex assembly and protein-transport-related pathways were especially enriched, which may be because a large number of proteins are synthesized during this process ([Figure 2](#fig2){ref-type="fig"}C). B-cell-activation-related pathways were also enriched ([Figure 2](#fig2){ref-type="fig"}C), and representative genes include *PRDM1*, *XBP1*, and *IRF4* ([Figure 2](#fig2){ref-type="fig"}D). The identity and function of plasma cells are dependent upon the transcription factors *PRDM1*, *XBP1*, and *IRF4* ([@bib16]; [@bib22]). *PRDM1* has a central role in determining and shaping the secretory arm of mature B cell differentiation and in promoting immunoglobulin (Ig) synthesis. *XBP1* is a positively acting transcription factor in the CREB-ATF family that is expressed at a large amounts in plasma cells and is crucial for increasing protein synthesis in plasma cells ([@bib22]). *IRF4* regulates immunoglobulin class-switch recombination, and sustained and higher concentrations of *IRF4* are known to promote the generation of plasma cells ([@bib16]). Following increased plasma cells and expression of relevant transcription factors, we found that the expression of *CD2AP* on activated CD4^+^ T cells was elevated compared with healthy controls ([Figure 2](#fig2){ref-type="fig"}E). The adaptor molecule CD2AP in CD4^+^ T cells modulates the differentiation of follicular helper T cells and improves protective antibody responses in viral infection ([@bib18]). In addition to supporting plasma cell function, *TNFSF14* expression was also increased in activated CD4^+^ T cells and cytotoxic CD8^+^ T cells. These factors promote T cell activation as well as T cell recruitment to tissues from peripheral blood. *KDM5A*, which encodes an H3K4me3 demethylase that is required for NK cell and T cell activation, is upregulated in NK cells and cytotoxic CD8^+^ T cells of COVID-19 ([Figure 2](#fig2){ref-type="fig"}E). Taken together, these results demonstrated that elevated plasma cells and increased activation of T cells and NK cells in COVID-19 patients may contribute to defense against the virus.Figure 2Dynamic Composition and Functional Changes in Immune Cells during SARS-CoV-2 Infection(A) The cell-type frequency in each sample. Bars are colored by cell types.(B) Differences in plasma and cycling plasma proportion among samples from healthy donors (Ctrl) (n = 3), COVID-19 patients (COV) (n = 16), and IAV patients (IAV) (n = 4). Student's t test was applied to test the significance of the difference. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(C) Enriched GO terms for upregulated genes in COVID-19 patients compared to healthy controls in B cells.(D) The differential expression levels of B cell activation-related genes *PRDM1*, *XBP1*, and *IRF4* between healthy donors (Ctrl) and COVID-19 patients (COV) in plasma cells.**(**E) The expression levels of T cell activation related genes in activated CD4^+^ T cells, cytotoxic CD8^+^ T cells, and NKs in samples from healthy donors and COVID-19 patients. In the upper panel, the color of each dot represents expression levels of the gene, while the dot size represents the fraction of cells expressing the gene in the specific cell type. In the lower panel, the difference between healthy donors (Ctrl) (n = 3) and COVID-19 patients (COV) (n = 16) were tested using the Student's t test. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.See also [Figure S2](#mmc1){ref-type="supplementary-material"} and [Table S2](#mmc3){ref-type="supplementary-material"}.

IFN Response and Lymphocyte Apoptosis in COVID-19 Patients {#sec2.3}
----------------------------------------------------------

Gene Ontology (GO) analyses were performed to gain insight into functions of different cell subsets between COVID-19 patients and healthy controls. Genes in the group "response to type I IFN signaling" were enriched in T, B, and NK cell subsets of D1 and D4, but not D16 samples ([Figures 3](#fig3){ref-type="fig"} A and [S3](#mmc1){ref-type="supplementary-material"}A), consistent with the concept that the IFN response is essential to the response triggered by viral infection. Consistently, "defense response to virus signaling" genes were also enriched in T, B, and NK cells of all five COVID-19 patients on D1 and D4, but not D16 ([Figures 3](#fig3){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A), implying an ongoing immune response against SARS-CoV-2 virus. Furthermore, endoplasm- and protein-unfolding-related pathways were especially enriched in B cells at all the three time points (D1, D4, and D16) ([Figures 3](#fig3){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A), which may be due to a higher proportion of plasma cells in B cell clusters because high demand of protein synthesis was required during antibody production. Other signaling pathways, such as "regulation of chromosome organization," "DNA conformation change," etc. in SARS-CoV-2 infection were also upregulated. The roles of these genes will need further investigation.Figure 3Analysis of IFN Response- and Apoptosis-Associated Genes in COVID-19 Patients(A) The top 20 enriched biological processes by GO analysis in day 1 samples from COVID-19 patients compared to healthy controls in different cell populations. Dot color indicates the statistical significance of the enrichment (p), and dot size represents gene ratio annotated to each term.(B) The differentially expressed genes in day 1 samples from COVID-19 patients compared to healthy controls in different cell subsets. Red dots represent genes upregulated in COVID-19 patients (adjusted p \< 0.01 and fold Change (FC) ≥ 2), while blue dots represent downregulated genes in COVID-19 patients (adjusted p \< 0.01 and FC ≤ 0.5). Genes with log~2~(FC) ≥ 1.5 were labeled by gene symbols.(C) The gene expression of *ISG15*, *IFI44L*, *MX1*, and *XAF1* in healthy donors (Ctrl) (n = 3) and COVID-19 patients (COV) (n = 16). Student's t test was applied to test the significance of the difference. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(D) Genes clustered by their expression pattern along the progression of the disease by the mfuzz R package.(E) The top 10 enriched biological processes in each cluster of genes as revealed by GO analysis.(F) The difference in expression levels of apoptosis-associated genes between COVID-19 patients (COV) (n = 5) and healthy controls (Ctrl) (n = 3) in T cells. Student's t test was applied. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.See also [Figure S3](#mmc1){ref-type="supplementary-material"} and [Table S3](#mmc4){ref-type="supplementary-material"}.

Differentially expressed genes (DEGs) in these transcriptomic profiles were then compared between COVID-19 patients and healthy controls. ISGs, which are vital to early viral control ([@bib21]), were identified in patients infected with SARS-CoV-2 on D1 and D4 ([Figures 3](#fig3){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}B), in line with the enrichment for "response to type I IFN signaling" pathways in our GO analysis ([Figures 3](#fig3){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A). Among these ISGs, *ISG15*, *IFI44L*, *MX1*, and *X-linked inhibitor of apoptosis* (*XIAP*)*-associated factor 1* (*XAF1*) were upregulated in T, B, NK, and DC cell subsets ([Figures 3](#fig3){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}B). The expression of these four genes was also much higher in COVID-19 patients compared to healthy controls at the bulk level ([Figure 3](#fig3){ref-type="fig"}C). We then examined transcription dynamics of these genes during the disease process. To achieve this, we divided the disease processes of COVID-19 patients from symptom onset to discharge into four stages ([Table S3](#mmc4){ref-type="supplementary-material"}). We identified six time-dependent expression patterns ([Figure 3](#fig3){ref-type="fig"}D) and investigated their biological significance ([Figure 3](#fig3){ref-type="fig"}E). Cluster 3 contained 158 genes that had decreased expression levels over time. The functions of these genes were significantly enriched in biological processes associated with IFN responses, indicating that the transcriptional regulation of these genes is dynamic and that they were activated at early time points and deactivated at late time points ([Figure 3](#fig3){ref-type="fig"}E). Cluster 1 contained 38 genes whose expression levels were elevated from stage 2. GO enrichment analysis showed that their functions were significantly enriched in translation and protein-synthesis-related pathways. This is consistent with the timing of antibody production ([@bib25]), since a large amount of proteins synthesis occurs during this process ([Figure 3](#fig3){ref-type="fig"}E).

Severe patient (COV-5) had a stronger response to IFNa upon SARS-CoV-2 infection than the mild patients did. In addition, the expression of *ISG15*, *IFI44L*, *MX1*, and *XAF1* was higher at earlier time points of disease progression and then decreased at later phases individually ([Figure S3](#mmc1){ref-type="supplementary-material"}C), illustrating their dynamic responses to interferons.

The ubiquitin-like protein ISG15, IFI44L, and MX1 all have roles in the antiviral response ([@bib17]), while XAF1 participates in pro-apoptotic responses and has been reported to form a positive feedback loop with IRF-1 that drives apoptosis under stress ([@bib10]). TP53-mediated apoptosis was also enhanced by XAF1 via post-translational modification ([@bib41]).Therefore, expression of genes linked to XAF1-mediated apoptosis, including *IRF1*, *TP53*, *BCL2L11*, and *CASP3,* was analyzed ([Figure S3](#mmc1){ref-type="supplementary-material"}D). Expression of *IRF1*, *TP53*, and *CASP3* was increased in T, B, and NK cell subsets in COVID-19 patients compared to controls, while *BCL2L11* exhibited different patterns in different cell subsets. In addition to the XAF1 related apoptosis pathway, expression of genes in other apoptosis-linked pathways, including TNF and Fas pathways ([@bib5]), was examined in both COVID-19 patients and healthy controls ([Figures 3](#fig3){ref-type="fig"}F and [S3](#mmc1){ref-type="supplementary-material"}E). The expression of *TNFSF10* (*TRAIL*) and its receptor *TNFRSF10A* were increased in T cells from COVID-19 patients relative to healthy controls. Other TNF path members, including *TNFRSF1B*, were also relatively upregulated in COVID-19 patients. As for the FAS path, the expression of *FAS*, *FASLG*, and *FADD* were upregulated in T cells of COVID-19 patients, though not significantly ([Figure 3](#fig3){ref-type="fig"}F). In B and NK cell subsets, *TNFSF10* and *FADD* were notably increased in COVID-19 patients with other genes increased mildly, except that *Fas* in B cells and *TRADD* in NK cells were subtly decreased ([Figure S3](#mmc1){ref-type="supplementary-material"}E). Taken together, we find that upregulated genes relevant to the XAF1, TNF, and Fas pathways may lead to increased T cell apoptosis in COVID-19 patients.

Immune Molecular Signatures of COVID-19 Patients Compared to IAV Patients {#sec2.4}
-------------------------------------------------------------------------

Next, we sought to identify the immune molecular signatures associated with COVID-19 and IAV infection. Thus, we compared the expression of cytokines, cytokine receptors, and transcription factors in T cell subsets, NK cells, and DCs among COVID-19 patients, IAV patients, and healthy controls ([Figures 4](#fig4){ref-type="fig"} A and [S4](#mmc1){ref-type="supplementary-material"}A). As the gene clustering pattern suggested, upregulated genes in COVID-19 patients mostly encode proinflammatory cytokines, cytokine receptors, and IFN-responsive transcription factors, while in IAV patients, proinflammatory transcription factors and virus-interacting host factors seem to be highly expressed.Figure 4Hallmarks of COVID-19 Compared to IAV (Revealed by Single-Cell Analysis of Cytokines, Cytokine Receptors, and Transcription Factors)(A) The relative expression level (*Z* score) of key cytokines, cytokine receptors, and transcription factors among COVID-19 patients, IAV patients, and healthy controls in the activated CD4^+^ T cells population.(B) The expression level of four representative genes highly expressed in activated CD4^+^ T cells of IAV patients. Upper panel: the color of each dot in the dot plot indicates expression level of the gene; dot size represents the fraction of cells expressing the gene in activated CD4^+^ T cells population. Lower panel: difference in gene expression among samples from COVID-19 patients (COV) (n = 16), IAV patients (IAV) (n = 4), and healthy donors (Ctrl) (n = 3). Each dot in the boxplot represents the average expression level of a gene in the activated CD4^+^ T cells population in one sample. Student's t test was applied to test the significance of the difference. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(C) Similar to (B), showing four representative genes highly expressed in the activated CD4^+^ T cells of COVID-19 patients.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Multiple key transcription factors involved in the host immune response, including *STAT3*, *NFKB1*, and *REL*, were upregulated in various cell types from IAV patients ([Figures 4](#fig4){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}A). *NFKB1* and *REL* encode active subunits of NF-κB heterodimer, one of the hallmark transcription factors activated by IAV infection ([@bib14]). Activation of NF-κB plays a key role in regulating the proinflammatory innate immune response and adaptive immune response. Previous work showed that IL-6 and IL-10, known activators of STAT3 signaling, are highly increased in severe IAV patients ([@bib34]). Expression of *STAT3* was elevated in IAV patients compared to COVID-19 patients and healthy controls and seemed to correlate with time post admission. In addition, *RUNX3* expression was upregulated in activated CD4^+^ T cells of IAV patients compared to the other groups ([Figure 4](#fig4){ref-type="fig"}B). It has been suggested that RUNX3 induction is a key step for CD4^+^ T cells to acquire cytotoxic activity, whereas another study showed that RUNX3 induced by IAV infection through the NF-κB pathway promoted apoptosis in airway epithelial cells ([@bib6]). The role of RUNX3 in the T-cell-mediated immune response remains to be determined. Several pro-viral host factors such as *CHD1*, *BCLAF1*, and *PHF3* that contribute to viral infection, replication, and immune evasion were also upregulated in IAV patients ([Figures 4](#fig4){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}A) ([@bib23]). To see how response of these genes changes over time, we divided the disease processes of IAV patients into two stages ([Table S3](#mmc4){ref-type="supplementary-material"}). We did not find any gene exhibiting statistically significant time-dependent regulation, although some them had trends toward increased or decreased expression ([Figures S4](#mmc1){ref-type="supplementary-material"}B and S4C).

For COVID-19 patients, STAT1, a major transcription factor activated in response to interferon, was upregulated in activated CD4^+^ T cells, cytotoxic CD8^+^ T cells, naive T cells, and DCs ([Figures 4](#fig4){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}A). Several proinflammatory factors, including TNF and TNFSF14, were elevated in activated CD4^+^ T cells, cytotoxic CD8^+^ T cells, MAIT cells, and NK cells ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4E), suggesting enhanced effector function and memory cell development ([@bib3]). Expression of *IL6* was not detectable in PBMCs of any patients or healthy controls. We measured plasma concentrations of IL-6 during hospitalization of these COVID-19 patients and after leaving the hospital ([Figure S4](#mmc1){ref-type="supplementary-material"}D). Plasma IL-6 were above the normal range (0.0--7.0 pg/mL) ([@bib2]) in two out of five patients when admitted to the hospital, dropped back to normal during hospitalization, and remained stable after recovery. There was a rising phase of IL-6 in most COVID-19 patients, indicating an active inflammatory response, which is also observed in IAV patients ([@bib34]). The patient with severe symptoms had a much higher level of IL-6 when hospitalized, and it took longer to return to normal plasma IL-6 levels, which corresponded to disease severity.

IL-6 exerts its function by binding to IL-6R. The IL-6-IL-6R complex then binds to GP130 (IL-6 receptor subunit beta \[IL6ST\]), a common signal-transducing chain shared by several related cytokines ([@bib15]). Expression of *IL6R* was elevated in activated CD4^+^ T cells, naive T cells, and DCs of COVID-19 patients compared to IAV patients and healthy controls ([Figures 4](#fig4){ref-type="fig"}C and [S4](#mmc1){ref-type="supplementary-material"}A). Meanwhile, expression of *IL6ST* was upregulated in various cell types from COVID-19 patients and IAV patients compared to healthy controls . It has been reported that IL-6R is often shed from the membrane of activated T cells, whereupon it binds the soluble form of IL-6 and acts *in trans* upon cells expressing IL6ST. Such IL-6 trans-signaling via IL6ST may contribute significantly to the proinflammatory properties of IL-6 ([@bib29]), emphasizing the potential importance of *IL6ST* upregulation observed in the current study.

Based on clinical observations that plasma concentrations of inflammatory cytokines, such as IFN-α2, IL-7, IL-17, and IL-10 were higher in COVID-19 patients than in healthy adults ([@bib9]), we compared expression levels of their corresponding receptors in activated CD4^+^ T cells, cytotoxic CD8^+^ T cells, MAIT cells, and NK cells across COVID-19 patients, IAV patients, and healthy controls. ([Figure S4](#mmc1){ref-type="supplementary-material"}E). Upregulation of IFNAR1, the α chain of the interferon α/β receptor, was significant in these cell types in COVID-19 patients compared to healthy controls. Notably, along with IFNAR1, receptor subunits for IL-7, IL-17, and IL-27 were substantially elevated in activated CD4^+^ T cells of COVID-19 patients compared to other groups, indicating that CD4^+^ T cells might be involved in major inflammatory response to cytokines.

Finally, we examined temporal changes in their expression ([Figures S4](#mmc1){ref-type="supplementary-material"}B and S4C). Although some IFN-responsive transcription factor genes, such as *STAT1* and *IRF3*, tend to have decreased expression levels over time, none of these patterns were statistically significant due to the limited number of patients. Future studies with more patients and more time points will address this question.

Discussion {#sec3}
==========

Emerging and re-emerging viruses pose a continuous threat to human health ([@bib7]). The new SARS-CoV-2 virus infection causes severe pulmonary disease and complications with significant morbidities and mortalities. Currently, there is no optimal treatment or effective drug for this fatal lung disease. Our current understanding of the host immune response to SARS-CoV-2 infection is limited, making it difficult to design urgently needed novel therapeutics. Here, we performed scRNA-seq on PBMCs from COVID-19 patients. Overall, the infection of SARS-CoV-2 has little impact on the composition of immune cells in PBMCs. Among all the immune cell clusters, the percentage of plasma cells was increased significantly among all five COVID-19 patients compared with healthy controls. This increase in plasma cells could produce multiple protective neutralizing antibodies. These B-cell-derived antibodies generated in response to SARS-CoV-2 are critical for preventing death from acute respiratory tract infections and providing continued protection from future infection-induced illness and/or death. In addition, blood plasma containing protective neutralizing antibodies from recovered patients is currently being encouraged for use to treat severely affected patients.

IFNs can be induced by viral infection to exert antiviral functions and balance virus control and immune pathology during this process. In SARS-CoV-2-infected ICU patients, plasma IFNγ and TNF-α levels were higher ([@bib9]). IFNα2 and IFNγ have also been strongly associated with lung injury in COVID-19 (Liu et al., 2020). In addition, IFNγ and granulocyte-macrophage colony-stimulating factor (GM-CSF) coexpressing Th1 cells were only found in intensive care unit (ICU) patients infected by SARS-CoV-2 compared to healthy controls ([@bib40]). Consistently, "IFN-I response" was enriched in different PBMC subsets of COVID-19 patients in our study. Furthermore, expression of ISGs, including *ISG15*, *IFI44L*, *MX1*, and *XAF1*, was significantly upregulated in these patients compared to three healthy controls, indicating that strong antiviral functions by IFNs may be triggered ([@bib17]). Moreover, severe COVID-19 patients showed a stronger response to IFNs and virus infection compared to mild patients and healthy ones. This indicates that the intensity of the interferon response may both indicate the severity of COVID-19 disease and distinguish COVID-19 patients from healthy individuals. Additionally, the dynamics of the IFN response suggest the individual differences and indicate that the timing of IFN therapy against SARS-CoV-2 infection is critical.

According to our results, upregulated *XAF1* expression may be involved in increased T cell apoptosis in COVID-19 patients, cooperating with other genes, including *IRF1*, *TP53*, *BCL2L11*, and *CASP3* ([@bib10]; [@bib41]). Consistently, *TP53* expression was increased in COVID-19 patients in another COVID-19 study ([@bib31]). In addition to XAF1-induced apoptosis, the extrinsic pathway of apoptosis, including TNF-α/TNFR1 and Fas/FasL path ([@bib5]), were also found to be involved in different cell subtypes in COVID-19 patients. Moreover, plasma TNF-α was reported to be increased in severe cases of COVID-19 ([@bib2]; [@bib9]), and TNF expression was upregulated in PBMCs of COVID-19 patients in our study, demonstrating a correlation between increased TNF-α secretion and TNF-α-induced apoptosis in COVID-19 patients ([@bib19]). XAF1 can be induced by TNF-α as well as IFN and functions as an alternative pathway for TNF-α-induced apoptosis ([@bib24]). XAF1 was also reported to collaborate with TNFSF10 (TRAIL) to promote Dengue virus-induced apoptosis ([@bib36]). Taken together, we found that the upregulated genes relevant to XAF1, TNF, and Fas pathways may lead to increased T cell apoptosis in COVID-19 patients.

We analyzed the expression of cytokines, cytokines receptors, and transcription factors that are essential in the immune responses to viral infection and pinpointed gene expression patterns in COVID-19 patients that differ from IAV patients. The upregulation of cytokine receptors was in accordance with increased serum cytokine levels, which might enhance the cytokine-mediated inflammatory responses. The fact that expression of most cytokines was not detected in PBMCs might indicate that serum cytokines largely arise from the infection site, i.e., the lower respiratory tract for COVID-19. We found that plasma concentrations of IL-6 are above normal levels in the majority of COVID-19 patients, consistent with other studies ([@bib2]). Elevated IL-6 was also reported in IAV patients ([@bib34]), and it is an immune signature in patients with acute respiratory stress syndrome ([@bib28]), which is associated with mortality caused by cytokine release syndrome. Currently, treatments blocking IL-6 or IL-6R have been approved for patients with pneumonia and elevated IL-6\], and a small-sized study has demonstrated the efficacy of Tocilizumab, a monoclonal antibody against IL-6R, in alleviating clinical symptoms ([@bib33]). Our data show that expression of *IL6R* and *IL6ST* was upregulated in patients with COVID-19, and we suggest that increased expression of *IL6R* and *IL6ST* might synergize with elevated IL-6 to induce a strong inflammatory response, indicating that patients might benefit from IL-6 or IL-6R antagonist treatment.

Limitations of the Study {#sec3.1}
------------------------

There are important limitations to the interpretation of this study. First, because only a limited number of patients were examined in our study, especially for IAV (two patients), the differences we identified between COVID-19 and IAV during infection need to be further validated by larger clinical trials and/or by further studies. Second, our study focuses on the single-cell transcriptome of PBMCs in blood. If we can combine our data with data from lesion sites such as the lung, our analysis will be more systematic and thus the conclusions would be more comprehensive.

Together, our study visualized the dynamic landscape of immune responses during the disease process in COVID-19 patients compared to IAV patients at the single-cell transcriptome level. These results not only represent the immune molecular and cellular signatures during the clinical process of COVID-19 but also suggest avenues to both diagnostic biomarkers and therapeutic targets, urgently needed for this novel disease.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Biological Samples**COVID-19 patients PBMCsFifth Medical Center of PLA General HospitalN/AIAV patients PBMCsBeijing Ditan Hospital, Capital Medical UniversityN/AHealthy control PBMCsFifth Medical Center of PLA General HospitalN/A**Critical Commercial Assays**QIAamp Viral RNA Mini KitQIAGENCat\#52904Novel Coronavirus (2019-nCoV) Nucleic Acid Detection kitBioGermCat\#ZC-HX-201-2DNBelab C Series Single-Cell Library Prep SetMGICat\#1000021082Qubit™ ssDNA Assay KitThermo Fisher ScientificCat\#Q10212Magnetic bead purificationMiltenyi BiotechCat\#130-090-101**Deposited Data**Data files for single-cell RNA sequencing (raw data)This paperCNP0001102Data files for single-cell RNA sequencing (processed data)This paperCNP0001102**Software and Algorithms**Cell Ranger Single-Cell Software Suite10xgenomicsversions 2.1.0 <http://10xgenomics.com/>STAR software(v2.5.3)Alex Dobin (<dobin@cshl.edu>), Cold Spring Harbor; [@bib4]N/ABowtie2Ben Langmead, Johns Hopkins University; [@bib11]N/ASeurat (v3.1) R toolkitSatija Lab<https://github.com/satijalab/seurat>Mfuzz[@bib43]<http://www.bioconductor.org/packages/release/bioc/html/Mfuzz.html>

Resource Availability {#sec4.2}
---------------------

### Lead Contact {#sec4.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, William Jun Liu (<liujun@ivdc.chinacdc.cn>).

### Materials Availability {#sec4.2.2}

All unique reagents generated in this study are available from the Lead Contact without restriction.

### Data and Code Availability {#sec4.2.3}

Raw and processed data are available on CNGB Nucleotide Sequence Archive (CNSA:<https://db.cngb.org/cnsa>) with accession number CNP0001102. The codes supporting the current study are available from the corresponding authors on request.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

Five patients with COVID-19 were recruited in the Fifth Medical Center of PLA General Hospital from January to February 2020. Patients were divided into mild and severe groups according to the Fifth Revised Trial Version of the Novel Coronavirus Pneumonia Diagnosis and Treatment Guidance. Influenza virus infection, respiratory syncytial virus infection and adenovirus infection were excluded in all patients with COVID-19. Two patients with IAV were recruited in the Beijing Ditan Hospital, Capital Medical University from January to February 2018. Two patients with IAV were diagnosed as having severe infection. The clinical characteristics of these patients are provided in [Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}.

Method Details {#sec4.4}
--------------

### Ethics statement {#sec4.4.1}

The study was approved by the Ethics Committees of the Fifth Medical Center of PLA General Hospital and Beijing Ditan Hospital, Capital Medical University. Written informed consent was obtained from all participants (including one from a teenager's parents).

### Clinical information {#sec4.4.2}

Throat swab and blood samples were collected from patients at various time-points after hospitalization. Sample collection, processing, and laboratory testing were conducted complied with WHO guidance. Viral RNA was extracted from throat swabs using the QIAamp Viral RNA Mini Kit (QIAGEN) according to the manufacturer's instructions. SARS-CoV-2-infected patients were confirmed SARS-CoV-2 Nucleic Acid Detection Kit (BioGerm).

All clinical information including demographic data, medical history, symptoms, signs, and laboratory data were collected from patient medical records. The laboratory data includes blood routine, lymphocyte subsets, infection-related biomarkers, inflammatory cytokines. The total number of leukocytes, percentage of neutrophils and percentage of lymphocytes in peripheral blood were counted using hemocytometer. The number and percentage of lymphocyte subsets were analyzed using the FACSCanto flow cytometer for COVID-19 patients on admission. C-reactive protein and Lactic acid were detected by the Beckman automatic biochemical analyzer. Interleukin 6 (IL-6) was detected using the ROCHE Elecsys IL-6 assay.

### Peripheral blood mononuclear cell (PBMC) collection {#sec4.4.3}

PBMCs were isolated from EDTA anticoagulated venous blood of COVID-19 patients, IAV patients or healthy donors using a FicollR Paque Plus (Sigma Aldrich) solution according to standard density gradient centrifugation methods. Cells were harvested and counted via Cellaca MX high-throughput cell counter (Nexcelom Bioscience). The PBMCs were resuspended in 90% fetal bovine serum (FBS, HyClone), 10% DMSO freezing media and frozen using a Nalgene® Mr. Frosty Cryo 1°C Freezing Container (Thermo Fisher Scientific) in a −80°C freezer for 24 h before being transferred to liquid nitrogen for long-term storage.

### Single-cell suspension preparation {#sec4.4.4}

Frozen vials of PBMCs were rapidly thawed in a 37°C water bath for ∼2 min, and the vials were removed when a tiny ice crystal was left. Thawed PBMCs were quenched with 4 mL 37°C pre-warmed 1X phosphate-buffered saline (PBS, Thermo Fisher Scientific) and supplemented with 10% FBS. Cells were centrifuged at 500 x g for 10 min at room temperature each time. The supernatant was removed, and the cell pellet was resuspended in 3 mL 1X PBS containing 0.04% bovine serum albumin (BSA, Sangon Biotech), passed through a 40 μm cell strainer (Falcon), and then centrifuged. Dead cells were removed by magnetic bead purification (Miltenyi Biotech) according to the manufacturer's protocol before scRNA-seq was performed. Cells were resuspended with cell resuspension buffer at a viable cell concentration of 1,000 cells/μL.

### Single-cell RNA-seq with DNBelab C4 system {#sec4.4.5}

The DNBelab C Series Single-Cell Library Prep Set (MGI) was utilized as previously described ([@bib44]) for single-cell RNA-seq library preparation. In brief, the single-cell suspensions were converted to barcoded scRNA-seq libraries through steps including droplet encapsulation, emulsion breakage, mRNA captured bead collection, reverse transcription, cDNA amplification and purification. Indexed sequencing libraries were constructed according to the manufacturer's protocol. The sequencing libraries were quantified by Qubit ssDNA Assay Kit (Thermo Fisher Scientific). The sequencing libraries were sequenced by the DIPSEQ T1 sequencer at China National GeneBank (CNGB). The read structure was paired-end with Read 1, covering 30 bases inclusive of 10-bp cell barcode 1, 10-bp cell barcode 2 and 10-bp unique molecular identifier (UMI), and Read 2 containing 100 bases of transcript sequence, and 10-bp sample index.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### Single-cell RNA-seq data processing (Alignment, Barcode Assignment, and UMI Counting). {#sec4.5.1}

The raw FASTQ files were transformed using custom Perl scripts into Cell Ranger-specific FASTQ files. These FASTQ files were then processed individually using a modified version of Cell Ranger count pipeline, which made use of the STAR software (v2.5.3) ([@bib4]) to align cDNA reads to the GRCh38.p5 human reference genome. Aligned reads were then filtered for valid cell barcodes and UMIs to generate gene-cell matrices for downstream analysis.

### Detection of SARS-CoV-2 transcript {#sec4.5.2}

The genome of SARS-CoV-2 was downloaded from NCBI (<https://www.ncbi.nlm.nih.gov/>) with the accession number GenBank:[NC_045512.2](ncbi-n:NC_045512.2){#intref0050}. The raw sequencing reads were then aligned to the genome by STAR (v2.5.3) ([@bib4]) and Bowtie2 ([@bib11]) using a modified annotation GTF file.

### Unsupervised clustering {#sec4.5.3}

Cell clustering was performed by Seurat (v3.1) R toolkit ([@bib1]) (<https://github.com/satijalab/seurat>). Genes expressed in less than 3 cells were filtered out and cells with less than 300 or more than 6000 genes detected were excluded. In order to deal with the batch effect, the "NormalizeData" and "FindVariableGene" functions were performed respectively for each sample (n = 23). After that, these 23 batches were integrated together using "FindIntergrationAnchors" and "IntegrateData" function with dims parameter set to 20. Then, the integrated dataset was scaled and PCA was calculated. The first 20 PCs were used to construct a SNN network and a graph-based clustering approach, louvain algorithm, was applied to identify cell clusters with the resolution set to 1. Finally, UMAP was applied to visualize the clustering result in 2D space. To further regress out the influence of red blood cells, we excluded this cluster of cells as well as 10 hemoglobin genes in the expression matrix (*HBA1*,*HBA2*, *HBB*, *HBG1*, *HBG2*, *HBQ1*, *HBD*, *HBM*, *HBE1* and *HBZ*), and performed clustering again using the same method described above.

### Cluster marker analysis and cell type annotation {#sec4.5.4}

To annotate each cluster to a specific immune cell type, we selected some classic markers for immune cells and used violin plots ([Figure 1](#fig1){ref-type="fig"}D) and UMAP feature plots ([Figure S1](#mmc1){ref-type="supplementary-material"}) to annotate cell types. The following genes were used for cell type annotation: CD3G, CD4, CD8A, CD8B (T cells); KLRF1, XCL1 (NKs); MS4A1 (B cells); CD27 (Memory B cells) IGHG1, MZB1 (Plasma cells); CD68 (Monocytes); CD1C, LYZ (DCs); MKI67, TOP2A (Cycling cells); GZMA (Cytotoxic CD8^+^ T cells / NKs); CCR7, SELL (Naive T cells); PPBP (Megakaryocytes); CD34 (Stem cells).

### Differential expressed genes (DEGs) analysis and GO enrichment {#sec4.5.5}

We performed DEG analysis using the "FindMarkers" function in Seurat R package. The cell populations we compared were input as ident.1 and ident.2, respectively. The fold changes of the mean expression level of genes between the selected cell populations were calculated. To find the function of upregulated genes (adjusted p \< 0.01, Foldchange \> 2), we used the function compareCluster (fun = \"enrichGO," pvalueCutoff = 0.1, pAdjustMethod = \"BH," OrgDb = \"org.Hs.eg.db,ontBP") of ChIPseeker R package (v.1.22.1) ([@bib35]).

### Identifying time dependent transcriptional program in COVID-19 patients {#sec4.5.6}

We used Mfuzz ([@bib43]) to identify time dependent transcriptional program in COVID-19 patients. The samples from COVID-19 patients were grouped according to the disease progression stage ([Table S3](#mmc4){ref-type="supplementary-material"}). First, the average expression of each gene was calculated for each stage. Next, we added 0.000001 for every gene to avoid 0 in the expression matrix which was not acceptable for Mfuzz. Then, the "filter.std(min.std=0)," "standardize()" and "mestimate()" functions were performed for preprocessing according to the tutorial. After that, we clustered the genes into 6 different expression programs ([Figure 3](#fig3){ref-type="fig"}D). For the GO analysis of the 6 programs, we first excluded genes with the maximum expression less than 1. Only GO terms with adjusted P value \< 0.05 were shown in the figure ([Figure 3](#fig3){ref-type="fig"}E).

### Boxplot {#sec4.5.7}

All of the boxplots in this paper were performed using "ggboxplot()" function in ggpubr R package. Each point represents for one sample. The sample number of each group was as follow: Healthy donors (Ctrl) (n = 3), COVID-19 patients (COV) (n = 16), IAV patients (IAV) (n = 4). The horizontal line within each box represents the median, and the top and bottom of each box indicate the 75th and 25th percentile. Student's t test was applied to test the significance of the difference using "stat_compare_means()" function.

Quantification and Statistical Analysis {#sec4.6}
---------------------------------------

Statistical analysis was performed using R (version 3.6.1). Wilcoxon rank-sum test and Student's t test were used in this study. ^∗^ p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.

Supplemental Information {#app2}
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Document S1. Figures S1--S4 Table S1. Clinical Data of the Enrolled Subjects, Related to Figure 1 Table S2. Clinical Laboratory Test, Related to Figure 2 Table S3. Disease Progression Stage Information, Related to Figure 3 Document S2. Article plus Supplemental Information
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